Cargando…

wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell cancer, characterized by the highest mortality rate among other RCC subtypes due to the occurrence of metastasis and drug resistance following surgery. The Von Hippel-Lindau tumor suppressor (VHL)-hypoxia-inducible fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Wierzbicki, Piotr M., Klacz, Jakub, Kotulak-Chrzaszcz, Anna, Wronska, Agata, Stanislawowski, Marcin, Rybarczyk, Agnieszka, Ludziejewska, Aleksandra, Kmiec, Zbigniew, Matuszewski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615924/
https://www.ncbi.nlm.nih.gov/pubmed/31268155
http://dx.doi.org/10.3892/ijo.2019.4830
_version_ 1783433424196861952
author Wierzbicki, Piotr M.
Klacz, Jakub
Kotulak-Chrzaszcz, Anna
Wronska, Agata
Stanislawowski, Marcin
Rybarczyk, Agnieszka
Ludziejewska, Aleksandra
Kmiec, Zbigniew
Matuszewski, Marcin
author_facet Wierzbicki, Piotr M.
Klacz, Jakub
Kotulak-Chrzaszcz, Anna
Wronska, Agata
Stanislawowski, Marcin
Rybarczyk, Agnieszka
Ludziejewska, Aleksandra
Kmiec, Zbigniew
Matuszewski, Marcin
author_sort Wierzbicki, Piotr M.
collection PubMed
description Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell cancer, characterized by the highest mortality rate among other RCC subtypes due to the occurrence of metastasis and drug resistance following surgery. The Von Hippel-Lindau tumor suppressor (VHL)-hypoxia-inducible factor 1 subunit α (HIF1A)/hypoxia-inducible factor 2α (HIF2A)-vascular endothelial growth factor A (VEGFA) protein axis is involved in the development and progression of ccRCC, whereas sunitinib, a tyrosine kinase inhibitor, blocks the binding of VEGFA to its receptor. The aim of the present study was to examine the possible association of the gene expression of VHL, HIF1A, HIF2A, VEGFA and tumor protein P53 (P53) in cancer tissue with the outcome of ccRCC patients who were treated with sunitinib as first-line therapy following nephrec-tomy. A total of 36 ccRCC patients were enrolled, 11 of whom were administered sunitinib post-operatively. Tumor and control samples were collected, and mRNA and protein levels were assessed by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. High mRNA and protein expression levels of HIF2A and VEGFA were found to be associated with shorter overall survival (OS) and progression-free survival (PFS) rates, as well as with unfavorable risk factors of cancer recurrence and mortality. Resistance to sunitinib was also observed; the OS and PFS rates were shorter (median OS and PFS: 12 and 6 months, respectively, vs. undetermined). Sunitinib resistance was associated with high HIF2A and VEGFA protein levels (b=0.57 and b=0.69 for OS and PFS, respectively; P<0.001). Taken together, the findings of this study suggest that the protein levels of HIF2A and VEGFA in tumor tissue may serve as independent prognostic factors in ccRCC. ccRCC patients with increased intratumoral HIF2A and VEGFA protein levels, and unaltered VHL protein levels, are not likely to benefit from sunitinib treatment following nephrectomy; however, this hypothesis requires verification by large-scale replication studies.
format Online
Article
Text
id pubmed-6615924
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-66159242019-07-30 wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment Wierzbicki, Piotr M. Klacz, Jakub Kotulak-Chrzaszcz, Anna Wronska, Agata Stanislawowski, Marcin Rybarczyk, Agnieszka Ludziejewska, Aleksandra Kmiec, Zbigniew Matuszewski, Marcin Int J Oncol Articles Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell cancer, characterized by the highest mortality rate among other RCC subtypes due to the occurrence of metastasis and drug resistance following surgery. The Von Hippel-Lindau tumor suppressor (VHL)-hypoxia-inducible factor 1 subunit α (HIF1A)/hypoxia-inducible factor 2α (HIF2A)-vascular endothelial growth factor A (VEGFA) protein axis is involved in the development and progression of ccRCC, whereas sunitinib, a tyrosine kinase inhibitor, blocks the binding of VEGFA to its receptor. The aim of the present study was to examine the possible association of the gene expression of VHL, HIF1A, HIF2A, VEGFA and tumor protein P53 (P53) in cancer tissue with the outcome of ccRCC patients who were treated with sunitinib as first-line therapy following nephrec-tomy. A total of 36 ccRCC patients were enrolled, 11 of whom were administered sunitinib post-operatively. Tumor and control samples were collected, and mRNA and protein levels were assessed by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. High mRNA and protein expression levels of HIF2A and VEGFA were found to be associated with shorter overall survival (OS) and progression-free survival (PFS) rates, as well as with unfavorable risk factors of cancer recurrence and mortality. Resistance to sunitinib was also observed; the OS and PFS rates were shorter (median OS and PFS: 12 and 6 months, respectively, vs. undetermined). Sunitinib resistance was associated with high HIF2A and VEGFA protein levels (b=0.57 and b=0.69 for OS and PFS, respectively; P<0.001). Taken together, the findings of this study suggest that the protein levels of HIF2A and VEGFA in tumor tissue may serve as independent prognostic factors in ccRCC. ccRCC patients with increased intratumoral HIF2A and VEGFA protein levels, and unaltered VHL protein levels, are not likely to benefit from sunitinib treatment following nephrectomy; however, this hypothesis requires verification by large-scale replication studies. D.A. Spandidos 2019-06-25 /pmc/articles/PMC6615924/ /pubmed/31268155 http://dx.doi.org/10.3892/ijo.2019.4830 Text en Copyright: © Wierzbicki et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wierzbicki, Piotr M.
Klacz, Jakub
Kotulak-Chrzaszcz, Anna
Wronska, Agata
Stanislawowski, Marcin
Rybarczyk, Agnieszka
Ludziejewska, Aleksandra
Kmiec, Zbigniew
Matuszewski, Marcin
wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
title wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
title_full wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
title_fullStr wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
title_full_unstemmed wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
title_short wPrognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
title_sort wprognostic significance of vhl, hif1a, hif2a, vegfa and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615924/
https://www.ncbi.nlm.nih.gov/pubmed/31268155
http://dx.doi.org/10.3892/ijo.2019.4830
work_keys_str_mv AT wierzbickipiotrm wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT klaczjakub wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT kotulakchrzaszczanna wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT wronskaagata wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT stanislawowskimarcin wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT rybarczykagnieszka wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT ludziejewskaaleksandra wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT kmieczbigniew wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment
AT matuszewskimarcin wprognosticsignificanceofvhlhif1ahif2avegfaandp53expressioninpatientswithclearcellrenalcellcarcinomatreatedwithsunitinibasfirstlinetreatment